PMID- 21286345
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1936-0541 (Electronic)
IS  - 1936-0533 (Print)
IS  - 1936-0533 (Linking)
VI  - 4
IP  - 4
DP  - 2010 Aug 12
TI  - Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in 
      patients with non-alcoholic fatty liver disease.
PG  - 741-8
LID - 10.1007/s12072-010-9202-6 [doi]
AB  - OBJECTIVE: The aim of this study was to explore the role of farnesoid X receptor 
      (FXR) in liver lipid metabolism of non-alcoholic fatty liver disease (NAFLD) 
      patients. METHODS: In this study, pathology and clinical criteria confirmed NAFLD 
      in patients. Fatty acid synthetase (FAS)-positive liver cells were visualized by 
      laser scanning confocal microscopy. Levels of FXR, liver X receptor (LXR), sterol 
      regulatory element binding protein 1C (SREBP-1C), and small heterodimer partner 
      (SHP) proteins were detected by Western blot. FXR, LXR, and SHP mRNA levels were 
      measured by real-time PCR. RESULTS: In patients with NAFLD, a significant 
      positive relationship between the degree of hepatic steatosis and serum 
      triglycerides and cholesterol (correlation coefficient > 0.5, P < 0.05) was seen. 
      The NAFLD patients had more FAS protein in liver, which suggests that there could 
      have been more of fatty acid synthesis in hepatic cells (P < 0.05). The levels of 
      FXR protein and mRNA were decreased in patients with NAFLD (P < 0.05), while 
      those of LXR and SREBP-1C were increased (P < 0.05). The levels of SREBP-1C 
      positively correlated with the degree of hepatic steatosis. There were no 
      differences between the levels of SHP protein and mRNA both in NAFLD patients and 
      normal controls (P > 0.05). CONCLUSION: Our data showed that the decreased 
      expression of hepatic FXR is associated with an increased expression of LXR, 
      SREBP-1C, and hepatic triglyceride synthesis; furthermore, increased SREBP-1C is 
      associated with the degree of hepatic steatosis in the NAFLD patients.
FAU - Yang, Zhao-Xia
AU  - Yang ZX
FAU - Shen, Wei
AU  - Shen W
FAU - Sun, Hang
AU  - Sun H
LA  - eng
PT  - Journal Article
DEP - 20100812
PL  - United States
TA  - Hepatol Int
JT  - Hepatology international
JID - 101304009
PMC - PMC2994619
OTO - NOTNLM
OT  - FXR
OT  - Human
OT  - Lipid metabolism
OT  - NAFLD
EDAT- 2011/02/03 06:00
MHDA- 2011/02/03 06:01
PMCR- 2010/08/12
CRDT- 2011/02/03 06:00
PHST- 2010/01/29 00:00 [received]
PHST- 2010/07/12 00:00 [accepted]
PHST- 2011/02/03 06:00 [entrez]
PHST- 2011/02/03 06:00 [pubmed]
PHST- 2011/02/03 06:01 [medline]
PHST- 2010/08/12 00:00 [pmc-release]
AID - 9202 [pii]
AID - 10.1007/s12072-010-9202-6 [doi]
PST - epublish
SO  - Hepatol Int. 2010 Aug 12;4(4):741-8. doi: 10.1007/s12072-010-9202-6.